Clinical Trial Update: Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia [NA]

View source ↗

Summary

The study investigating human umbilical cord-derived mesenchymal stem cells for refractory immune thrombocytopenia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Human Umbilical Cord-derived Mesenchymal Stem Cells (mesenchymal stem cells)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Thrombocytopenia, Mesenchymal Stem Cells | NA | Status: COMPLETED